Aligos Therapeutics (ALGS) Non-cash Items (2019 - 2026)

Aligos Therapeutics has reported Non-cash Items for 8 years, with the latest figure at $206000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-cash Items fell 17.96% year-over-year to $206000.0; the trailing twelve-month figure through Mar 2026 stood at $206000.0 (down 17.96% YoY), and the FY2025 full-year result was $55234.0, down 99.48% from the prior year.
• Non-cash Items for Q1 2026 stood at $206000.0, down from $859000.0 in the prior quarter.
• The five-year high for Non-cash Items was $10.6 million in Q4 2024, with the low at $33000.0 in Q2 2025.
• Historically, Non-cash Items has averaged $3.0 million across 5 years, with a median of $3.1 million in 2024.
• Annual changes were most pronounced in 2023 — Non-cash Items soared 3775.37% — and 2025, when it tumbled 99.04%.
• Aligos Therapeutics' Non-cash Items stood at $3.7 million in 2022, then surged by 62.19% to $6.0 million in 2023, then surged by 75.4% to $10.6 million in 2024, then slumped by 91.9% to $859000.0 in 2025, then plunged by 76.02% to $206000.0 in 2026.
• The last three Non-cash Items figures came in at $206000.0 (Q1 2026), $859000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.